



## **Task Force for the Regulation of FDA Approved Psychedelic Medicines**

*An Act establishing the Alaska task force for the regulation of psychedelic medicines approved by the US Food and Drug Administration; and providing for an effective date.*

CSHB 228 (STA) am - 33-LS0976\T.A

### **Summary of Differences with Companion CSSB 166 (JUD) – 33-LS1062\N**

1. The title of the task force has been changed in HB 228 from the “Alaska mental health and psychedelic medicine task force” to the “Alaska task force for the regulation of psychedelic medicines approved by the United States Food and Drug Administration.” This change was made to better represent the duties of the task force. This change is reflected in the title of the bill, in the beginning of section 1 (page 1 lines 7 to 9), and in section 1(h).
2. A new paragraph has been added to HB 228 as section 1(b)(11), and the following subsections were renumbered. The new section 1(b)(11) reads, “one member who is a pharmacist, selected by the board of directors of the Alaska Pharmacy Association.”
3. The language in section 1(b)(10) of SB 166, which reads, “one member of the faculty of the division of population health sciences at the University of Alaska, selected by the president of the University of Alaska,” was deleted from HB 228 and following subsections were renumbered.
4. A new paragraph has been added to HB 228 as section 1(b)(7), and the following subsections were renumbered. The new section 1(b)(7) reads, “one member who is a physician or osteopath specializing in behavioral health, selected by the Board of Trustees of the Alaska State Medical Association.”
5. The language in section 1(b)(7) of SB 166, which reads “one member representing the psychiatric profession, selected by the governing body of the Alaska Psychiatric Association” was reworded in HB 228’s equivalent section 1(b)(8) to read, “one member who is a physician or osteopath specializing in psychiatry, selected by the governing body of the Alaska Psychiatric Association.”
6. The number of members the task force could appoint after assembling under section 1(b)(13) of SB 166 was reduced from three to one in HB 228’s equivalent section, 1(b)(14).



**Summary of Differences Between CSHB 228 (STA) am and Companion CSSB 166 (JUD)  
(continued)**

7. The language in section 1(c) of SB 166, which reads, “The task force shall elect a chair from among its members,” was deleted and replaced in HB 228 with language that reads, “The members appointed by the president of the senate and the speaker of the house of representatives under (b)(12) and (13) of this section shall serve as co-chairs of the task force. A member appointed under (b)(12) or (13) of this section may select a designee to attend a meeting of the task force on the member’s behalf.”
8. The date the task force’s report is due to the legislature and the governor was moved to January 31, 2025 in HB 228, from December 31, 2024 in SB 166. The task force’s termination date was moved to the end of the first session of the Thirty-Fourth Legislature, where in SB 166 the task force terminates the day the Thirty-Fourth Legislature convenes.
9. The language in section 1(a)(1) in SB 166 reads, “assess the potential use of psychedelic medicine in addressing the state’s ongoing mental health crisis, as well as in treating chronic and terminal illnesses and in end-of-life care.” Section 1(a)(1) of HB 228 was not amended to include the second and third clauses and reads, “assess the potential use of psychedelic medicine in addressing the state’s ongoing mental health crisis.”